| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-078 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 3、本次股东会未涉及变更以往股东会已通过的决议。 一、会议召开和出席情况 2025年第四次临时股东会决议公告 （一）会议召开情况 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 1、会议的通知：蓝帆医疗股份有限公司（以下简称"公司"）于2025年9月5日在 《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨潮资讯网 （http://www.cninfo.com.cn）上刊登了会议通知。 特别提示： 1、为尊重中小投资者利益，提高中小投资者对公司股东会决议的重大事项参与度， 本次股东会审议议案对中小投资者单独计票。中小投资者是指除上市公司董事、高级 管理人员以及单独或合计持有上市公司5%以上股份的股东以外的其他股东。 2、本次股东会未出现否决议案的情形。 2、会议召开的日期、时间： （1）现场会议时间：2025 年 9 月 22 日（星期一）下 ...

上海锦天城（青岛）律师事务所 关于蓝帆医疗股份有限公司 2025 年第四次临时股东会的 法律意见书 地址：青岛市市南区香港中路 8 号青岛中心大厦 45 层 电话：(0532) 55769077 传真：(0532) 55769155 邮编：266071 上海锦天城（青岛）律师事务所 法律意见书 上海锦天城（青岛）律师事务所 关于蓝帆医疗股份有限公司 2025 年第四次临时股东会的 法律意见书 致蓝帆医疗股份有限公司： 上海锦天城（青岛）律师事务所（以下简称"本所"）接受蓝帆医疗股份 有限公司（以下简称"公司"或"蓝帆医疗"）的委托，指派靳如悦、冉令帅 律师出席了公司于 2025 年 9 月 22 日召开的 2025 年第四次临时股东会（以下简 称"本次股东会"）。现根据《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）和《上市 公司股东会规则》（以下简称"《股东会规则》"）、《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、规 范性文件以及《蓝帆医疗股份有限公司章程》（以下简称"《公司章程》"） 的规定，对本次股东 ...

证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-079 债券代码：128108 债券简称：蓝帆转债 表决结果：同意票 8 票，反对票 0 票，弃权票 0 票。 第六届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第三十次会议于2025年 9月19日以电子邮件的方式发出通知，于2025年9月22日在公司上海商业总部第一会议 室以现场及通讯表决相结合的方式召开。本次会议应参加会议董事8人，实际参加会议 董事8人；刘文静女士、李振平先生、钟舒乔先生、赵永清先生以现场的方式出席会议， 于苏华先生、赵敏女士、乔贵涛先生、刘海波先生以通讯的方式出席会议。公司董事 长刘文静女士主持了本次会议。会议的通知、召开、表决程序符合《中华人民共和国 公司法》和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 审议并通过了《关于向下修正"蓝帆转债"转股价格的议案》。 公司2025 年第四次临时股东会召开日前二十个交易日公司股票交易均价为人民币 6.08 ...

Group 1 - The core point of the article is that Bluestar Medical announced a board meeting to discuss the adjustment of the conversion price of "Bluestar Convertible Bonds" [1] - For the first half of 2025, Bluestar Medical's revenue composition is as follows: 70.08% from rubber and plastic products, 24.88% from specialized equipment manufacturing, 3.72% from other manufacturing, and 1.32% from other businesses [1] - As of the report, Bluestar Medical has a market capitalization of 5.7 billion yuan [1] Group 2 - The article highlights a national large-scale procurement that has drawn significant attention from the industry due to concerns over low bidding prices [1]

Core Insights - The company, Bluestar Medical, reported that its cardiovascular division generates approximately 60% of its revenue from international markets and 40% from domestic markets, with expectations for an increase in domestic revenue share in the future [1] - In the first half of 2025, the company's cardiovascular division is projected to achieve nearly 700 million yuan in revenue, with around 650 million yuan coming from coronary business and 50 million yuan from heart valve business [1]

Core Viewpoint - Blue Sail Medical (002382) anticipates a gradual increase in nitrile glove prices in the first half of 2024 due to various market dynamics, including high inventory levels in the U.S. and shifts in production strategies among manufacturers [1] Industry Summary - Nitrile glove prices have reached historical lows, with expectations for recovery driven by market conditions [1] - U.S. customer inventory levels are currently high, impacting the operating rates of Malaysian glove manufacturers, which may lead to increased competition in non-U.S. markets [1] - As U.S. market inventories are gradually consumed, procurement demand is expected to recover, potentially directing more orders towards Malaysian production [1] - Adjustments in business strategies by some companies towards more rational approaches are likely to positively influence the recovery of nitrile glove prices [1]

Core Viewpoint - The company, Bluefan Medical, announced on September 19 that it has three production bases for nitrile gloves, with plans to enhance energy efficiency through a new partnership for combined heat and power generation [1] Group 1: Production Bases - The company operates three production bases for nitrile gloves [1] - The Shandong Health Technology production base currently uses a coal-fired boiler [1] - The company has recently acquired a partnership with Weifang Green Source Thermal Power Co., Ltd. to potentially achieve combined heat and power generation, which is expected to improve energy advantages [1] Group 2: Energy Costs - The Zibo Bluefan Protection and Zibo Health Technology bases rely on purchased steam as their energy source, leading to higher energy costs [1] - The company is actively exploring solutions to address the high costs associated with purchased steam [1]

证券日报网讯蓝帆医疗（002382）9月19日发布公告，在公司回答调研者提问时表示，血管内冲击波碎 石术(IVL)2025年上半年营收有几千万元，主要来源于国内市场，海外市场也已实现商业化应用。 ...

Core Viewpoint - The company emphasizes its focus on drug-coated balloons and specialized balloons as key development areas, highlighting the competitive advantage of rapamycin-based drug balloons [1] Group 1: Company Strategy - The company's development strategy aims to achieve integrated solutions while adhering to the concept of "intervention without implantation" [1] - The company plans to pursue both horizontal and vertical development, with horizontal development involving a range of product lines such as drug-coated balloons, specialized balloons, and intravascular imaging [1] - Vertical development focuses on the renewal and upgrading of existing products [1]

Group 1 - The core viewpoint of the article is that Bluestar Medical (002382) announced on September 19 that its health protection business, specifically PVC and nitrile gloves, is expected to maintain a high capacity utilization rate of over 80% in the first half of 2025, positioning it among the industry leaders [1]